Events & Presentations Upcoming Events No upcoming events at this time Past Events SVB Securities Virtual Global Biopharma Conference 2023 Feb 16, 2023 at 2:20 PM EST Click here for webcast Investor Presentations ARS Corporate Presentation ARS Corporate Presentation 3.6 MB Scientific Publications JACI 2023 Single and Repeat Dose Publication Pharmacokinetics/pharmacodynamics of epinephrine after single and repeat admini… Scientific Presentations ACAAI 2023 Poster 7 Acute Allergic Rhinitis Increases Endogenous Epinephrine Resulting in Increased Heart Rate 678.5 KB ACAAI 2023 Poster 12 A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of 2.0 mg neffy to Pediatric Subjects with a History of Allergic Reactions 806.5 KB ACAAI 2023 Poster 18 Pharmacokinetics/Pharmacodynamics of Intranasal Epinephrine in Subjects with and without Upper Respiratory Infections 522.5 KB AAAAI 2023 Poster 8 A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of Intranasal ARS-1 (neffy® Nasal Spray) to Pediatric Subjects with a History of Systemic Allergic Reactions 1.1 MB AAAAI 2023 Poster 14 ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Epinephrine Injection Products: An Integrated Pharmacokinetic Analysis 1.1 MB AAAAI 2023 Poster 20 Use of Over-the-Counter Products to Treat Severe Allergic Reactions Before an Epinephrine Auto-Injection (EAI) Device: Results of a Patient/Caregiver Survey 745.7 KB AAAAI 2023 Poster 28 Epinephrine Auto-Injector (EAI) Prescriptions Are Not Filled Due to Dislike of Needles: Results of a Patient Survey 2.2 MB AAAAI 2023 Poster 9 Pharmacokinetics of Self-Administration of ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Manual Intramuscular (IM) Epinephrine 0.3 mg by Health Care Provider (HCP) 2.5 MB ACAAI 2022 Poster 238 Pharmacokinetics/Pharmacodynamics After Single and Repeat Administration of ARS-1 (neffy® Nasal Spray), Epinephrine Auto-Injector, and Manual Intramuscular Injection 2.2 MB ACAAI 2022 Poster 237 ARS-1 (neffy® Nasal Spray) and Intramuscular Injection: Pharmacokinetic/Pharmacodynamic Differences and Differential Affinities for Adrenergic Receptors 3.4 MB Pagination Current page 1 Page 2 Next page next › Last page last »
Investor Presentations ARS Corporate Presentation ARS Corporate Presentation 3.6 MB Scientific Publications JACI 2023 Single and Repeat Dose Publication Pharmacokinetics/pharmacodynamics of epinephrine after single and repeat admini… Scientific Presentations ACAAI 2023 Poster 7 Acute Allergic Rhinitis Increases Endogenous Epinephrine Resulting in Increased Heart Rate 678.5 KB ACAAI 2023 Poster 12 A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of 2.0 mg neffy to Pediatric Subjects with a History of Allergic Reactions 806.5 KB ACAAI 2023 Poster 18 Pharmacokinetics/Pharmacodynamics of Intranasal Epinephrine in Subjects with and without Upper Respiratory Infections 522.5 KB AAAAI 2023 Poster 8 A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of Intranasal ARS-1 (neffy® Nasal Spray) to Pediatric Subjects with a History of Systemic Allergic Reactions 1.1 MB AAAAI 2023 Poster 14 ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Epinephrine Injection Products: An Integrated Pharmacokinetic Analysis 1.1 MB AAAAI 2023 Poster 20 Use of Over-the-Counter Products to Treat Severe Allergic Reactions Before an Epinephrine Auto-Injection (EAI) Device: Results of a Patient/Caregiver Survey 745.7 KB AAAAI 2023 Poster 28 Epinephrine Auto-Injector (EAI) Prescriptions Are Not Filled Due to Dislike of Needles: Results of a Patient Survey 2.2 MB AAAAI 2023 Poster 9 Pharmacokinetics of Self-Administration of ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Manual Intramuscular (IM) Epinephrine 0.3 mg by Health Care Provider (HCP) 2.5 MB ACAAI 2022 Poster 238 Pharmacokinetics/Pharmacodynamics After Single and Repeat Administration of ARS-1 (neffy® Nasal Spray), Epinephrine Auto-Injector, and Manual Intramuscular Injection 2.2 MB ACAAI 2022 Poster 237 ARS-1 (neffy® Nasal Spray) and Intramuscular Injection: Pharmacokinetic/Pharmacodynamic Differences and Differential Affinities for Adrenergic Receptors 3.4 MB Pagination Current page 1 Page 2 Next page next › Last page last »
A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of 2.0 mg neffy to Pediatric Subjects with a History of Allergic Reactions 806.5 KB
Pharmacokinetics/Pharmacodynamics of Intranasal Epinephrine in Subjects with and without Upper Respiratory Infections 522.5 KB
A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of Intranasal ARS-1 (neffy® Nasal Spray) to Pediatric Subjects with a History of Systemic Allergic Reactions 1.1 MB
ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Epinephrine Injection Products: An Integrated Pharmacokinetic Analysis 1.1 MB
Use of Over-the-Counter Products to Treat Severe Allergic Reactions Before an Epinephrine Auto-Injection (EAI) Device: Results of a Patient/Caregiver Survey 745.7 KB
Epinephrine Auto-Injector (EAI) Prescriptions Are Not Filled Due to Dislike of Needles: Results of a Patient Survey 2.2 MB
Pharmacokinetics of Self-Administration of ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Manual Intramuscular (IM) Epinephrine 0.3 mg by Health Care Provider (HCP) 2.5 MB
Pharmacokinetics/Pharmacodynamics After Single and Repeat Administration of ARS-1 (neffy® Nasal Spray), Epinephrine Auto-Injector, and Manual Intramuscular Injection 2.2 MB
ARS-1 (neffy® Nasal Spray) and Intramuscular Injection: Pharmacokinetic/Pharmacodynamic Differences and Differential Affinities for Adrenergic Receptors 3.4 MB
